Apo-Semaglutide Injection : Incorrect dose display

Product Apo-Semaglutide Injection Issue Health products - Product quality What to do Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concerns. Distribution Alberta British Columbia Manitoba New Brunswick Newfoundland and Labrador Ontario Quebec

The affected lot may display a dose of 0.25 mg or 0.5 mg in the dose window and deliver one of these doses instead of the expected 1 mg dose.

Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concerns. Contact the recalling firm if you have any questions about the recall. Report any health product related side effects to Health Canada. Report any other health product safety complaints to Health Canada.

RA-82679